Literature DB >> 25159205

Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions.

Anna E Koopmans1, Kimberley Ober2, Hendrikus J Dubbink2, Dion Paridaens3, Nicole C Naus4, Stephan Belunek2, Bart Krist2, Edward Post2, Ellen C Zwarthoff2, Annelies de Klein5, Robert M Verdijk2.   

Abstract

PURPOSE: Hot-spot mutations in the promoter region of telomerase reverse transcriptase (TERT promoter mutations) occur frequently in cutaneous and conjunctival melanoma and are exceedingly rare in uveal melanoma. No information is available on the presence of these mutations in the conjunctival melanocytic precursor lesion primary acquired melanosis (PAM). We tested a cohort of uveal and conjunctival melanomas as well as conjunctival benign and premalignant melanocytic lesions for TERT promoter mutations in order to elucidate the role of these mutations in tumor progression.
METHODS: TERT promoter mutation analysis on fresh tumor DNA and DNA from formalin-fixed, paraffin-embedded specimens was performed by SNaPshot analysis in 102 uveal melanomas, 39 conjunctival melanomas, 26 PAM with atypia, 14 PAM without atypia, and 56 conjunctival nevi.
RESULTS: Mutations of the TERT promoter were not identified in conjunctival nevi or PAM without atypia, but were detected in 2/25 (8%) of PAM with atypia and 16/39 (41%) of conjunctival melanomas. A single TERT promoter mutation was detected in 102 uveal melanomas (1%).
CONCLUSIONS: We present the second documented case of TERT promoter mutation in uveal melanoma. In comparison with other types of melanoma, TERT promoter mutations occur at extremely low frequency in uveal melanoma. TERT promoter mutations are frequent in conjunctival melanoma and occur at lower frequency in PAM with atypia but were not detected in benign conjunctival melanocytic lesions. These findings favor a pathogenetic tumor progression role for TERT promoter mutations in conjunctival melanocytic lesions. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.

Entities:  

Keywords:  BRAF; TERT; conjunctival melanoma; mutation; nevus; primary acquired melanosis; uveal melanoma

Mesh:

Substances:

Year:  2014        PMID: 25159205     DOI: 10.1167/iovs.14-14901

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  25 in total

1.  [Conjunctival malignancies].

Authors:  Claudia Auw-Hädrich; Thomas Reinhard
Journal:  Ophthalmologe       Date:  2019-10       Impact factor: 1.059

2.  Molecular Characteristics of Conjunctival Melanoma Using Whole-Exome Sequencing.

Authors:  Swarup S Swaminathan; Matthew G Field; David Sant; Gaofeng Wang; Anat Galor; Sander R Dubovy; J William Harbour; Carol L Karp
Journal:  JAMA Ophthalmol       Date:  2017-12-01       Impact factor: 7.389

3.  Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.

Authors:  C Mircea S Tesileanu; Linda Dirven; Maarten M J Wijnenga; Johan A F Koekkoek; Arnaud J P E Vincent; Hendrikus J Dubbink; Peggy N Atmodimedjo; Johan M Kros; Sjoerd G van Duinen; Marion Smits; Martin J B Taphoorn; Pim J French; Martin J van den Bent
Journal:  Neuro Oncol       Date:  2020-04-15       Impact factor: 12.300

Review 4.  [Ocular melanomas : An update].

Authors:  H Kalirai; P L Müller; D Jaehne; S E Coupland
Journal:  Pathologe       Date:  2017-11       Impact factor: 1.011

5.  Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.

Authors:  Hendrikus J Dubbink; Peggy N Atmodimedjo; Johan M Kros; Pim J French; Marc Sanson; Ahmed Idbaih; Pieter Wesseling; Roelien Enting; Wim Spliet; Cees Tijssen; Winand N M Dinjens; Thierry Gorlia; Martin J van den Bent
Journal:  Neuro Oncol       Date:  2015-09-09       Impact factor: 12.300

6.  Single Time Frame Overview of the Genetic Changes in Conjunctival Melanoma from Intraepithelial Disease to Invasive Melanoma: A Study of 4 Exenteration Specimens Illustrating the Potential Role of Cyclin D1.

Authors:  Hardeep Singh Mudhar; Sachin S Salvi; Daniel Pissaloux; Arnaud de La Fouchardiere
Journal:  Ocul Oncol Pathol       Date:  2021-11-17

7.  Histopathological and Molecular Features of a Conjunctival Caruncular Deep Penetrating Nevus.

Authors:  Jolique A van Ipenburg; Jeffrey Damman; Dion Paridaens; Robert M Verdijk
Journal:  Ocul Oncol Pathol       Date:  2020-01-28

Review 8.  Understanding TERT Promoter Mutations: A Common Path to Immortality.

Authors:  Robert J A Bell; H Tomas Rube; Ana Xavier-Magalhães; Bruno M Costa; Andrew Mancini; Jun S Song; Joseph F Costello
Journal:  Mol Cancer Res       Date:  2016-03-03       Impact factor: 5.852

9.  Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial.

Authors:  C Mircea S Tesileanu; Marc Sanson; Wolfgang Wick; Alba A Brandes; Paul M Clement; Sara C Erridge; Michael A Vogelbaum; Anna K Nowak; Jean-Francois Baurain; Warren P Mason; Helen Wheeler; Olivier L Chinot; Sanjeev Gill; Matthew Griffin; Leland Rogers; Walter Taal; Roberta Rudà; Michael Weller; Catherine McBain; Myra E van Linde; Kenneth Aldape; Robert B Jenkins; Johan M Kros; Pieter Wesseling; Andreas von Deimling; Youri Hoogstrate; Iris de Heer; Peggy N Atmodimedjo; Hendrikus J Dubbink; Rutger W W Brouwer; Wilfred F J van IJcken; Kin Jip Cheung; Vassilis Golfinopoulos; Brigitta G Baumert; Thierry Gorlia; Pim J French; Martin J van den Bent
Journal:  Clin Cancer Res       Date:  2022-06-13       Impact factor: 13.801

10.  Molecular Genetics of Conjunctival Melanoma and Prognostic Value of TERT Promoter Mutation Analysis.

Authors:  Natasha M van Poppelen; Jolique A van Ipenburg; Quincy van den Bosch; Jolanda Vaarwater; Tom Brands; Bert Eussen; Frank Magielsen; Hendrikus J Dubbink; Dion Paridaens; Erwin Brosens; Nicole Naus; Annelies de Klein; Emine Kiliç; Robert M Verdijk
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.